Intratumoral administration was for the first cohort, the second...

Intratumoral administration was for the first cohort, the second cohort had both intratumoral and intraventricular dosing.

But we can't underestimate the importance of broadening awareness of this trial, as CLTX has already garnered significant interest (evidenced through the many publications already available) even before it hit the clinic. Now it is in the clinic, management are showcasing its progress through brain cancer conferences in the US where leaders and decision makers in the field will be made aware of CLTX if they haven't already.

I draw comparison to IMU who present frequently at global conferences like ESMO and have also presented at other prestigious conferences such as the American Association of Cancer Research, and American Society of Clinical Oncology. Getting invited to present at these are a sign that your management / clinical results are being noticed and seen valuable enough to warrant a time slot, which makes it an invaluable opportunity to gain exposure in your target market and may go a long way to ensure maximum value is attributed to any success your trial may achieve.

If a biotech you are investing in can't get on the agenda at these global or US conferences in the field you are looking to treat... you are well behind the market and are facing an uphill battle. Some biotechs CEOs spend more time talking to investor conferences ramping a stock than they do at conferences in the field they are targeting.. just something to look out for when investing in biotechs.